News
XOMA Corp Entered Into A Merger Agreement To Acquire Kinnate Biopharma For A Base Cash Price Per Share Of $2.3352 Per Share And An Additional Cash Amount Of Not More Than $0.2527 Per Share
19 Mar 24
M&A
HC Wainwright & Co. Maintains Buy on XOMA, Maintains $74 Price Target
11 Mar 24
News, Price Target, Analyst Ratings
Recap: XOMA Q4 Earnings
8 Mar 24
Earnings
XOMA FY GAAP EPS $(4.04) May Not Be Comparable To $(2.05) Estimate, Sales $4.76M Miss $6.50M Estimate
8 Mar 24
Earnings, News
HC Wainwright & Co. Reiterates Buy on XOMA, Maintains $74 Price Target
16 Feb 24
News, Price Target, Reiteration, Analyst Ratings
Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma
16 Feb 24
Biotech, M&A, News, Health Care, Movers, Trading Ideas, General
Press releases
XOMA Declares Quarterly Preferred Stock Dividends
21 Mar 24
News, Dividends, Press Releases
KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
13 Mar 24
Press Releases
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
8 Mar 24
Earnings, Press Releases
XOMA to Present at Upcoming Investor Conferences in March
28 Feb 24
News, Press Releases
KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
19 Feb 24
Press Releases
Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA
16 Feb 24
Press Releases
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
16 Feb 24
M&A, News, Press Releases